These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Induction of antibody responses to breast carcinoma associated mucins using synthetic peptide constructs as immunogens. Denton G; Sekowski M; Price MR Cancer Lett; 1993 Jul; 70(3):143-50. PubMed ID: 7689035 [TBL] [Abstract][Full Text] [Related]
8. Removal of xenoreactive human anti-pig antibodies by absorption on recombinant mucin-containing glycoproteins carrying the Gal alpha1,3Gal epitope. Liu J; Qian Y; Holgersson J Transplantation; 1997 Jun; 63(11):1673-82. PubMed ID: 9197365 [TBL] [Abstract][Full Text] [Related]
10. Humoral immunity against a tandem repeat epitope of human mucin MUC-1 in sera from breast, pancreatic, and colon cancer patients. Kotera Y; Fontenot JD; Pecher G; Metzgar RS; Finn OJ Cancer Res; 1994 Jun; 54(11):2856-60. PubMed ID: 7514493 [TBL] [Abstract][Full Text] [Related]
11. A fucose residue can mask the MUC-1 epitopes in normal and cancerous gastric mucosae. Bara J; Imberty A; Pérez S; Imai K; Yachi A; Oriol R Int J Cancer; 1993 Jun; 54(4):607-13. PubMed ID: 7685744 [TBL] [Abstract][Full Text] [Related]
12. Definition and characterization of chicken Gal alpha(1,3)Gal antibodies. McKenzie IF; Patton K; Smit JA; Mouhtouris E; Xing P; Myburgh JA; Sandrin MS Transplantation; 1999 Mar; 67(6):864-70. PubMed ID: 10199735 [TBL] [Abstract][Full Text] [Related]
13. Epitope mapping of anti-breast and anti-ovarian mucin monoclonal antibodies. Xing PX; Prenzoska J; McKenzie IF Mol Immunol; 1992 May; 29(5):641-50. PubMed ID: 1374842 [TBL] [Abstract][Full Text] [Related]
14. Identification and characterization of a galactosyl peptide mimetic. Implications for use in removing xenoreactive anti-A Gal antibodies. Kooyman DL; McClellan SB; Parker W; Avissar PL; Velardo MA; Platt JL; Logan JS Transplantation; 1996 Mar; 61(6):851-5. PubMed ID: 8623148 [TBL] [Abstract][Full Text] [Related]
15. Defining carbohydrate specificity of Ricinus communis agglutinin as Gal beta 1-->4GlcNAc (II) > Gal beta 1-->3GlcNAc (I) > Gal alpha 1-->3Gal (B) > Gal beta 1-->3GalNAc (T). Wu JH; Herp A; Wu AM Mol Immunol; 1993 Mar; 30(4):333-9. PubMed ID: 7681148 [TBL] [Abstract][Full Text] [Related]
16. Gal alpha (1,3)Gal, the major xenoantigen(s) recognised in pigs by human natural antibodies. Sandrin MS; McKenzie IF Immunol Rev; 1994 Oct; 141():169-90. PubMed ID: 7532618 [TBL] [Abstract][Full Text] [Related]
17. Immune recognition of human colonic-tumour-associated MUC-2 mucins using an anti-peptide antibody. Price MR; Sekowski M; Ladányi A; Uray K; Ma Y; Durrant L; Tendler SJ Int J Cancer; 1993 Nov; 55(5):753-9. PubMed ID: 7503958 [TBL] [Abstract][Full Text] [Related]
18. Use of sialylated or sulfated derivatives and acrylamide copolymers of Gal beta 1,3GalNAc alpha- and GalNAc alpha- to determine the specificities of blood group T- and Tn-specific lectins and the copolymers to measure anti-T and anti-Tn antibody levels in cancer patients. Chen Y; Jain RK; Chandrasekaran EV; Matta KL Glycoconj J; 1995 Feb; 12(1):55-62. PubMed ID: 7795413 [TBL] [Abstract][Full Text] [Related]
19. Protective Epitope Discovery and Design of MUC1-based Vaccine for Effective Tumor Protections in Immunotolerant Mice. Wu X; Yin Z; McKay C; Pett C; Yu J; Schorlemer M; Gohl T; Sungsuwan S; Ramadan S; Baniel C; Allmon A; Das R; Westerlind U; Finn MG; Huang X J Am Chem Soc; 2018 Dec; 140(48):16596-16609. PubMed ID: 30398345 [TBL] [Abstract][Full Text] [Related]
20. Carbohydrate/peptide mimics: effect on MUC1 cancer immunotherapy. Apostolopoulos V; Sandrin MS; McKenzie IF J Mol Med (Berl); 1999 May; 77(5):427-36. PubMed ID: 10426192 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]